Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NVP-LAF237

Known as: NVP-LAF-237 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vildagliptin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
Abstract Background Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
NVP‐AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells. This… Expand
2015
2015
The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study
Paclitaxel exhibits clinical activity against a wide variety of solid tumors. However, resistance to paclitaxel significantly… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2010
Highly Cited
2010
89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
Background:Heat-shock protein 90 (Hsp90) has a crucial role in both the stabilisation and regulation of various proteins… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2009
2009
The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo
Shifting substrate oxidation in heart muscle from fatty acids to glucose (substrate-switch) may improve contractile function in… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
2008
2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which is expressed in a subpopulation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and… Expand
Highly Cited
2002
Highly Cited
2002
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
OBJECTIVE Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the… Expand
  • figure 1—24
  • figure 2
  • table 1
  • table 2
Highly Cited
2002
Highly Cited
2002
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
OBJECTIVES Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE